FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894878286> ?p ?o ?g. }

• W2894878286 endingPage "1072" @default.
• W2894878286 startingPage "1063" @default.
• W2894878286 abstract "Objective: The aim of this study was to investigate the effects of sitagliptin on the regulation of free fatty acid (FFA) and other metabolic parameters in drug-naïve subjects with type 2 diabetes mellitus (T2DM). Methods: This was a prospective, nonrandomized, observational study. Drug-naïve subjects with T2DM received 25 to 50 mg/day sitagliptin monotherapy (n = 64). At 3 months, FFA and other metabolic parameters were compared with those at baseline. FFA was measured by colorimetry with enzymatic reactions. As a comparator, 12.5 to 25 mg/day alogliptin monotherapy was given to drug-naïve subjects with T2DM (n = 55). Results: Significant reductions in FFA (-13.2%, P<0.01) levels were observed with sitagliptin but not alogliptin. Both drugs showed similar glycemic efficacies. Significant correlations were observed between the changes (Δ) of FFA and Δglycated hemoglobin A1c (HbA1c), Dtotal cholesterol (TC), Δnon-high-density lipoprotein cholesterol (HDL-C), or Δlow-density lipoprotein cholesterol (LDL-C), and significant negative correlations were seen between ΔFFA and Δhomeostasis model assessment-B (HOMA-B), ΔC-peptide immunoreactivity (CPR)-index or Δbody mass index (BMI) in the sitagliptin group. The subjects in the sitagliptin group were further divided into 2 subgroups (n = 32 each) according to the changes of FFA (group B [above the median] ΔFFA = 23.1 %, P<.0005; group A [below the median] ΔFFA = -37.3 %, P<.00001). At baseline, FFA levels were significantly higher in group A versus group B (P<.001). Higher degrees of reductions of FBG (-14.6% vs. -9.3%, P<0.05) or HbA1c (-20.6% vs. -16.9%, P<.05), and increases of HOMA-B (52.7% vs. 38.3%, P<.03) or CPR-index (37.5% vs. 18.8%, P<.02) were observed in group A versus group B. Significant reductions of TC (-5.8%, P<.002), non-HDL-C (-7.8%, P<.001) or LDL-C (-6.3%, P<.02), and significant increases of C-peptide (11.3%, P<.05) were seen only in group A. Conclusion: Sitagliptin could downregulate high FFA levels. Subjects with reductions of FFA levels had better glycemic efficacies and higher degrees of enhancement of beta-cell function than others. Reductions of atherogenic cholesterols were seen in these populations. Abbreviations: CPR = C-peptide immunoreactivity; DPP-4 = dipeptidyl peptidase 4; FBG = fasting blood glucose; FFA = free fatty acid; HbA1c = glycated hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; HOMA-R = homeostasis model assessment-R; HOMA-B = homeostasis model assessment-B; non-HDL-C = non-HDL-cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; T2DM = type 2 diabetes; TG = triglyceride; UA = uric acid" @default.
• W2894878286 created "2018-10-12" @default.
• W2894878286 creator A5015460546 @default.
• W2894878286 creator A5033887168 @default.
• W2894878286 creator A5070028378 @default.
• W2894878286 date "2018-12-01" @default.
• W2894878286 modified "2023-09-25" @default.
• W2894878286 title "Regulation of Free Fatty Acid by Sitagliptin Monotherapy in DRUG-NAÏVE Subjects with Type 2 Diabetes" @default.
• W2894878286 cites W1540732733 @default.
• W2894878286 cites W1554365987 @default.
• W2894878286 cites W1767165379 @default.
• W2894878286 cites W1967900945 @default.
• W2894878286 cites W1975806460 @default.
• W2894878286 cites W1984413737 @default.
• W2894878286 cites W1991969856 @default.
• W2894878286 cites W2002711503 @default.
• W2894878286 cites W2020468088 @default.
• W2894878286 cites W2029491503 @default.
• W2894878286 cites W2038103428 @default.
• W2894878286 cites W2040811347 @default.
• W2894878286 cites W2045799771 @default.
• W2894878286 cites W2047399305 @default.
• W2894878286 cites W2053749316 @default.
• W2894878286 cites W2069295502 @default.
• W2894878286 cites W2074515136 @default.
• W2894878286 cites W2079731322 @default.
• W2894878286 cites W2080866420 @default.
• W2894878286 cites W2102182695 @default.
• W2894878286 cites W2127197277 @default.
• W2894878286 cites W2142830692 @default.
• W2894878286 cites W2145437385 @default.
• W2894878286 cites W2148899505 @default.
• W2894878286 cites W2316502270 @default.
• W2894878286 cites W2320160630 @default.
• W2894878286 cites W2474716574 @default.
• W2894878286 cites W2503232483 @default.
• W2894878286 cites W2602922176 @default.
• W2894878286 cites W2610297457 @default.
• W2894878286 doi "https://doi.org/10.4158/ep-2018-0287" @default.
• W2894878286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30289315" @default.
• W2894878286 hasPublicationYear "2018" @default.
• W2894878286 type Work @default.
• W2894878286 sameAs 2894878286 @default.
• W2894878286 citedByCount "8" @default.
• W2894878286 countsByYear W28948782862019 @default.
• W2894878286 countsByYear W28948782862020 @default.
• W2894878286 countsByYear W28948782862021 @default.
• W2894878286 countsByYear W28948782862023 @default.
• W2894878286 crossrefType "journal-article" @default.
• W2894878286 hasAuthorship W2894878286A5015460546 @default.
• W2894878286 hasAuthorship W2894878286A5033887168 @default.
• W2894878286 hasAuthorship W2894878286A5070028378 @default.
• W2894878286 hasConcept C126322002 @default.
• W2894878286 hasConcept C134018914 @default.
• W2894878286 hasConcept C2777180221 @default.
• W2894878286 hasConcept C2777538456 @default.
• W2894878286 hasConcept C2778763485 @default.
• W2894878286 hasConcept C2779284873 @default.
• W2894878286 hasConcept C2780012697 @default.
• W2894878286 hasConcept C2780221984 @default.
• W2894878286 hasConcept C2780473172 @default.
• W2894878286 hasConcept C2910068830 @default.
• W2894878286 hasConcept C2910260750 @default.
• W2894878286 hasConcept C555293320 @default.
• W2894878286 hasConcept C71924100 @default.
• W2894878286 hasConcept C90924648 @default.
• W2894878286 hasConceptScore W2894878286C126322002 @default.
• W2894878286 hasConceptScore W2894878286C134018914 @default.
• W2894878286 hasConceptScore W2894878286C2777180221 @default.
• W2894878286 hasConceptScore W2894878286C2777538456 @default.
• W2894878286 hasConceptScore W2894878286C2778763485 @default.
• W2894878286 hasConceptScore W2894878286C2779284873 @default.
• W2894878286 hasConceptScore W2894878286C2780012697 @default.
• W2894878286 hasConceptScore W2894878286C2780221984 @default.
• W2894878286 hasConceptScore W2894878286C2780473172 @default.
• W2894878286 hasConceptScore W2894878286C2910068830 @default.
• W2894878286 hasConceptScore W2894878286C2910260750 @default.
• W2894878286 hasConceptScore W2894878286C555293320 @default.
• W2894878286 hasConceptScore W2894878286C71924100 @default.
• W2894878286 hasConceptScore W2894878286C90924648 @default.
• W2894878286 hasIssue "12" @default.
• W2894878286 hasLocation W28948782861 @default.
• W2894878286 hasOpenAccess W2894878286 @default.
• W2894878286 hasPrimaryLocation W28948782861 @default.
• W2894878286 hasRelatedWork W1779028784 @default.
• W2894878286 hasRelatedWork W1987248351 @default.
• W2894878286 hasRelatedWork W2037029106 @default.
• W2894878286 hasRelatedWork W2042160152 @default.
• W2894878286 hasRelatedWork W2047379913 @default.
• W2894878286 hasRelatedWork W2319145410 @default.
• W2894878286 hasRelatedWork W2592585663 @default.
• W2894878286 hasRelatedWork W2596250353 @default.
• W2894878286 hasRelatedWork W4205965838 @default.
• W2894878286 hasRelatedWork W2496840989 @default.
• W2894878286 hasVolume "24" @default.
• W2894878286 isParatext "false" @default.
• W2894878286 isRetracted "false" @default.
• W2894878286 magId "2894878286" @default.

• next